Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (468)	6/14/1999 9:16:00 PM
From: SemiBull	Respond to of 712

COR Therapeutics, Inc. Announces Management Changes SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--June 14, 1999--COR Therapeutics, Inc. (Nasdaq: CORR - news) today announced changes to its management team. Effective September 1, 1999, Laura A. Brege, Senior Vice President, Finance and Chief Financial Officer will leave the Company to become a partner in a venture capital firm focused on seed and early stage software companies. Mrs. Brege has served as Chief Financial Officer for COR since 1992. ''Laura has played a key role on COR Therapeutics' management team. In addition, she has been responsible for building the Company's finance and administrative infrastructure necessary to support COR at our current size and complexity. We wish her every success in her new endeavors. We will miss her,'' said Vaughn M. Kailian, President and Chief Executive Officer of COR. In addition, Todd J. Lorenz, M.D. was promoted to Vice President, Medical Affairs. He was previously Senior Director, Clinical Research. COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction, deep vein thrombosis and restenosis. For additional information about COR Therapeutics, please visit the Company's Web site at corr.com.

To: LLCF who wrote (468)	7/6/1999 5:40:00 PM
From: RCMac	Read Replies (1) \| Respond to of 712

Integrelin approved for European sale (http://biz.yahoo.com/prnews/990706/schering_p_1.html ) and CORR yawns. Here is the text of the SGP PR: Tuesday July 6, 8:16 am Eastern Time Company Press Release SOURCE: Schering-Plough Corporation Schering-Plough Announces EU Approval of INTEGRILIN(R) for the Prevention of Early Myocardial Infarction in Patients Presenting with Unstable Angina or Non-Q-Wave Myocardial Infarction MADISON, N.J., July 6 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP - news) announced today that the European Union's (EU) Commission of the European Communities has granted marketing authorization to INTEGRILIN® (eptifibatide) Injection for the prevention of early myocardial infarction in patients with unstable angina (UA) or non-Q-wave myocardial infarction (NQMI), serious heart conditions known collectively as acute coronary syndromes (ACS), who are managed medically and/or with percutaneous coronary intervention (PCI). European Commission approval of the centralized Marketing Authorization Application for INTEGRILIN results in a single marketing authorization with unified labeling that is immediately valid in all 15 European Union-Member States. The approval follows a positive recommendation by the European Agency for the Evaluation of Medicinal Products' (EMEA) Committee for Proprietary Medicinal Products (CPMP) in February 1999. Schering-Plough will launch and market INTEGRILIN in Europe. It is marketed in the United States by COR Therapeutics, Inc. (Nasdaq: CORR - news) and Key Pharmaceuticals, a pharmaceutical marketing unit of Schering-Plough. INTEGRILIN is a member of a new class of drugs known as platelet receptor GP IIb-IIIa inhibitors. A landmark global trial known as PURSUIT (Platelet IIb-IIIa in Unstable Angina: Receptor Suppression Using INTEGRILIN Therapy) served as the basis for the marketing application authorization. PURSUIT demonstrated that INTEGRILIN significantly reduces the combined incidence of death or myocardial infarction (MI) in patients admitted to the hospital with UA or NQMI. Results of PURSUIT were published in the August 13, 1998 issue of The New England Journal of Medicine. The study found that INTEGRILIN was effective in reducing the incidence of death or MI in the 30 days following an episode of UA or NQMI regardless of whether the patient was receiving drug therapy alone or in combination with invasive cardiac procedures. Bleeding is the most common complication encountered during INTEGRILIN therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo. Contraindications include, but are not limited to, a history of bleeding diathesis or stroke, evidence of abnormal bleeding within the previous 30 days, recent major surgery, or concomitant use of a GP IIb-IIIa inhibitor. ''The evidence clearly suggests that the use of GP IIb-IIIa inhibitors should be considered a new standard of care in the management of ACS,'' said Professor Maarten Simoons, Erasmus University and University Hospital Dijkzigt in Rotterdam, the Netherlands, and principal European PURSUIT investigator. ''With PURSUIT and other clinical studies of its kind confirming the benefit of this therapeutic class, we have the opportunity to advance the treatment of patients suffering from acute coronary syndromes.'' The cost-effectiveness of eptifibatide in treating cases of ACS compared to other cardiac interventions in Western Europe was evaluated as part of a prospective substudy of PURSUIT. ''It is the patient who ultimately reaps the benefits of this therapy,'' said Professor Karl Karsch, University of Tubingen, Germany and the German country coordinator for PURSUIT. Worldwide hospitalizations for UA and NQMI are estimated to be in excess of 2 million patients annually. Approximately 1 million patients in Europe suffer from ACS. In the United States, ACS are the leading cause of admission to coronary care units; approximately 10 to 12 percent of these patients develop myocardial infarction and 2 to 5 percent die within 30 days of experiencing UA or NQMI. In the United States, INTEGRILIN received Food and Drug Administration (FDA) marketing clearance in May 1998 for treatment of patients with ACS (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). INTEGRILIN is also indicated in the United States for the treatment of patients undergoing PCI. Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide. INTEGRILIN is a registered trademark of COR Therapeutics, Inc.